Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 632 participants.

Also called NCT03860935

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 632 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03860935
  • EudraCT 2018-004280-32
Other papers using this trial's data
  • Comparison of in-clinic assessment of 6MWT by conventional method and using wearable sensors for patients with ATTR-CM Future cardiology, 2025-02 DOI, PubMed 39878480, PMC11812369 In the PMC Open Access subset under CC BY-NC-ND.
  • Contemporary Oral Medication Use and Frequency in Patients with Transthyretin Amyloid Cardiomyopathy American journal of cardiovascular drugs : drugs, devices, and other interventions, 2025-11 DOI, PubMed 40750720, PMC12594741 In the PMC Open Access subset under CC BY-NC.
  • Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy Journal of the American College of Cardiology, 2025-05-27 DOI, PubMed 40398971
  • Effect of Acoramidis on Heart Failure-Related Health Status: A Secondary Analysis of the ATTRibute-CM Randomized Clinical Trial JAMA cardiology, 2026-09-01 DOI, PubMed 42525404, PMC13420175 In the PMC Open Access subset under CC BY-NC-ND.
  • Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy The New England journal of medicine, 2024-01-11 DOI, PubMed 38197816
  • Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy Journal of the American College of Cardiology, 2025-03-18 DOI, PubMed 40074465
  • Natriuretic Peptide and Transthyretin and Their Relationship With Clinical Outcomes: Results From ATTRIBUTE-CM, a Randomized Controlled Trial Journal of the American Heart Association, 2026-10-06 DOI, PubMed 42669902

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Belgium, Brazil, Canada, Czechia, Denmark, Greece, Ireland, Israel, Italy, Netherlands, New Zealand, Poland, Portugal, South Korea, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03860935. Randomized; quadruple masking; primary purpose treatment. Start 2019-03-19 (actual); primary completion 2023-05-11 (actual). Results posted on 2024-06-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy
Acronym
ATTRibute-CM
Condition
Amyloidosis
Condition
Amyloid Cardiomyopathy
Condition
Transthyretin Amyloidosis
Condition
Cardiomyopathies
Condition
Heart Diseases
Intervention (Drug)
acoramidis
Intervention (Drug)
Placebo Oral Tablet
Lead sponsor
Eidos Therapeutics, a BridgeBio company (class: industry)

Record details

Record id
cardio:ct-nct03860935
Content hash
4a099f745615b2c928303258f31c28da7aefcafa40aac69c0deb88ad34516fb4